Navigation Links
uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
Date:12/14/2018

uBiome, the leader in microbial genomics, announced the issue of patent number 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent and Trademark Office on July 11, 2017 with a priority date of October 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. Jessica Richman, and Dr. Siavosh Rezvan Behbahani, and expands upon previously filed intellectual property.

The patented technology involves characterizing an immune-microbial dysfunction and generating a therapy model by analyzing biological samples from uBiome’s proprietary database. The microbiome compositions obtained with these products are useful in assisting a health care provider with the diagnosis of immune-microbial dysfunctions such as irritable bowel syndrome (IBS), Crohn’s disease, ulcerative colitis, and celiac disease, among others.

This issuance creates the possibility of designing a therapy based on the modification of the microbiota using prebiotics and probiotics. It also opens up the possibility of predicting the likelihood of occurrence of immune-microbial dysfunction in individuals.

“uBiome’s goal is to advance the science of the microbiome, and this technology allows us to do just that,” Jessica Richman, PhD, co-founder and CEO of uBiome, said. “Diagnostics and therapeutics are an exciting frontier for microbiome-derived analysis and we are pleased to have been granted this patent.”

For more information about our science and patents, visit http://www.ubiome.com/science/#patents.
_____
About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Read the full story at https://www.prweb.com/releases/ubiome_receives_patent_for_microbiome_derived_diagnostics_and_therapeutics_for_immune_microbial_dysfunction/prweb15986048.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Appoints Dr. Amir Zarrinpar, MD, PhD, Assistant Professor in the Division of Gastroenterology at UC San Diego, to its Medical Advisory Board
2. uBiome Appoints Dr. Brandon Wuerth, MD, Founder of IBDwatch, to its Medical Advisory Board
3. uBiome Appoints Dr. Emeran Mayer, MD, World-Renowned Gastroenterologist and Neuroscientist, to its Medical Advisory Board
4. uBiome Appoints Dr. Jill Carnahan, MD, Functional Medicine Expert, to its Medical Advisory Board
5. uBiome Appoints Dr. Catherine Lozupone, PhD, Respected Microbiologist, to its Scientific Advisory Board
6. uBiome Appoints Leading Biochemist Dr. Joseph DeRisi to Board of Directors
7. uBiome Appoints Dr. Donnica Moore, MD, Women's Health Expert and Advocate, to its Medical Advisory Board
8. uBiome Appoints Dr. Jonathan Braun, MD, PhD, Prominent UCLA Physician-Researcher, to its Scientific Advisory Board
9. uBiome Appoints Kathie Swift, MS, RDN, FAND, Co-founder of the Integrative and Functional Nutrition Academy, to its Scientific Advisory Board
10. uBiome Appoints Dr. Steven Medwell, MD, Distinguished Colorectal Surgeon, to its Medical Advisory Board
11. NDA Partners Expert Consultant Vinod Shah, PhD, Receives AAPS Award for Global Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... ... May 26, 2020 , ... ... for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., a clinical-stage biotechnology ... T cell engagers and TCR-based therapeutics, has implemented Genedata Biologics ® ...
(Date:5/21/2020)... ... , ... Law Enforcement has always been a highly stressful career – serving ... these men and women put them constantly in harm’s way both from the criminal ... always had to face very high daily stress. Now, COVID-19 introduces another even greater ...
(Date:5/14/2020)... ... May 14, 2020 , ... The annual salary report by ... 2019 average medical sales rep total compensation increased by $12,000 over the previous ... COVID-19 global crisis. , The MedReps 2020 Salary Survey revealed yet again there’s ...
Breaking Biology News(10 mins):
(Date:4/7/2020)... (PRWEB) , ... April 06, 2020 , ... Gateway ... future children, reached 200,000 SneakPeek Early Gender DNA Tests sold in March, ... was launched as an ecommerce product, where a mom could order her kit ...
(Date:4/1/2020)... Texas (PRWEB) , ... March 30, 2020 , ... ... (APMD) and telehealth developer Reliant Immune Diagnostics (RID), formed earlier this year to ... COVID-19 pandemic by creating in-home tests for COVID-19. Company officials are currently?awaiting an ...
(Date:4/1/2020)... ... 31, 2020 , ... Bedoukian Research, Inc. (BRI) ... Development Agreement that builds on each company’s expertise in developing efficient routes to ... supply of high-quality insect pheromones as well as flavors and fragrances. P2 has ...
(Date:3/19/2020)... ... March 17, 2020 , ... ... manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) ... cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human ...
Breaking Biology Technology: